Navigation Links
Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results

Conference Call To Be Held Thursday, May 15, 2008 at 9:00 a.m. Eastern Time

HOPKINTON, Mass., May 14 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reports operational and financial results for the quarter ended March 31, 2008 and provides further information for fiscal year 2008. Recent highlights include:
- Encouraging 12 month interim results from the Phase I/IIa Cethrin(R)

clinical trial in acute spinal cord injury

- Entry into an option agreement which provides the Company with an

option to amend its Cethrin license to lower milestone payments and

royalty rates in exchange for a fee

- Expansion of sites for the first stage of the Parkinson's or Essential

Tremor, or POET-2, Altropane(R) Phase III clinical trial program

- $5 million raised in March 2008

"Our programs continue to show promising progress," said Peter G. Savas, Chairman and Chief Executive Officer of Alseres. "We are encouraged by the unprecedented sensory and motor recovery seen in patients treated with Cethrin in our Phase I/IIa clinical trial. Key opinion leaders with whom we have spoken are highly impressed by the efficacy findings in the study. Armed with these results and after discussions with regulatory authorities and expert advisors, we were able to reduce the planned size of our Phase IIb clinical trial from 200 patients to a maximum of 100 patients providing us with potential time savings and cost reductions."


"We plan to start this trial in acute cervical spinal cord injury patients in the second half of this year," Savas noted. "Our recent agreement to improve the terms of the Cethrin license may represent a major step forward for Alseres in realizing the full value of our Cethrin spinal cord program and our Rho inhibitor technology platform and may open up key partnering opportunities."

Recent Corporate Highlights

- The 12 month interim results from the Phase I/IIa Cethrin clinical

trial in acute spinal cord injury show promising neurological recovery

in severely injured acute cervical spinal cord injury patients treated

with Cethrin. The trial enrolled a total of 48 patients of which 37

have reached the full 12 month follow up evaluation. The data for

these first 37 patients indicate that at 6 and 12 months after

treatment, 38% (5/13) of cervical injury patients showed marked

recovery of motor and sensory function after treatment as measured by a

2-grade or better improvement in the American Spinal Injury

Association, or ASIA, Impairment Scale. Subgroup analysis of ASIA

grade by dose group indicate that Cethrin doses of 1 and 3 mg appear to

be the most beneficial for cervical patients with 43% (3 of 7) showing

the same 2-grade or better recovery of motor and sensory function. In

addition, one cervical patient in each of the 1 and 3 mg dose groups

showed a 3-grade improvement to AIS D.

- We entered into an option agreement whereby the Company can exercise

its option to amend certain terms of the Cethrin license with BioAxone

Therapeutic, Inc. in exchange for a fee of $7 million. If Alseres

exercises this option, the pre-commercial milestone payments in the

amended license agreement will be reduced from $25 million to

$7 million payable on or before December 31, 2009. In addition, the

sales-based royalties in the amended license agreement will be reduced

from 10-12% to 4% for spinal cord injury and 1% for all other

indications. Finally, the amended license agreement will eliminate all

development milestones.

- In April 2008, Alseres announced the expansion in the number of sites

now open for enrollment in the first stage of the Altropane POET-2

Phase III clinical trial program. The sites participating in the first

stage of the POET-2 clinical trial program are: 1) University of

Alabama, Birmingham, AL, Principal Investigator: Ray Watts, M.D.;

2) University of Arizona Medical Center, Tucson, AZ, Principal

Investigator: Scott Sherman, M.D.; 3) Cedars-Sinai Medical Center,

Los Angeles, CA, Principal Investigator: Alan Waxman, M.D.;

4) University of Florida McKnight Brain Institute, Gainesville, FL,

Principal Investigator: Ramon Rodriguez, M.D.; 5) Dartmouth-Hitchcock

Medical Center, Lebanon, NH, Principal Investigator: David Coffey,

M.D.; 6) University of Texas Houston Medical School, Houston, TX,

Principal Investigator: Mya Schiess, M.D.; 7) University of Texas

Southwestern Medical Center, Dallas, TX, Principal Investigator:

Padraig O'Suilleabhain, M.D.

- On March 18, 2008, the Company entered into a Third Amended and

Restated Convertible Promissory Note Purchase Agreement among Robert L.

Gipson, Thomas Gipson, Arthur Koenig, Ingalls & Snyder Value Partners,

L.P. and Highbridge International LLC (each a "Purchaser"). The

agreement provides for the Company to borrow, in addition to the

$25 million already borrowed from the Purchasers, $5 million from

Robert L. Gipson, an existing Purchaser. The agreement further

provides that the Company may borrow up to an additional $5 million

from any Purchaser on the terms and conditions in the agreement. All

other terms of the agreement remained the same.

Financial Highlights of the First Quarter 2008

- Cash, cash equivalents and marketable securities at March 31, 2008

totaled $4.9 million as compared to $4.2 million at December 31, 2007.

Convertible notes payable totaled $28.1 million at March 31, 2008 as

compared to $23.3 million at December 31, 2007.

- Net loss attributable to common stockholders was $5.3 million, or $0.26

per share, for the first quarter of 2008, as compared to $4.1 million,

or $0.25 per share, in the first quarter of 2007.

- Research and development (R&D) expenses totaled $2.7 million in the

first quarter of 2008 as compared to $2.6 million in the first quarter

of 2007. The increase in R&D expenses was primarily due to higher

headcount and Cethrin clinical costs offset by lower costs in our

molecular imaging program.

- General and administrative (G&A) expenses totaled $2.2 million for the

first quarter of 2008 as compared to $1.6 million in the first quarter

of 2007. The increase in G&A expenses was primarily related to higher

headcount, higher patent and related costs and higher commercialization

and communication costs.

Alseres Pharmaceuticals Upcoming Milestones

- We intend to move forward with our previously announced plans for the

Cethrin Phase IIb trial in acute spinal cord injury in the second half

of 2008. The Company is currently identifying appropriate sites and

investigators for the study. The trial will be a double-blind,

randomized, placebo-controlled, multi-center, Phase IIb trial in up to

100 subjects with acute cervical SCI conducted at up to 80 sites in the

United States, Canada, Europe and other selected countries.

- We will continue enrollment in the first part of the POET-2 Phase III

clinical trial for Altropane molecular imaging agent. The trial calls

for enrollment of up to 80 subjects to generate an image training set.

These images will be used to train the expert readers in the study, as

is customary for clinical trials of molecular imaging agents.

- We are pursuing development and commercialization partnerships for our

molecular imaging, nerve repair and regenerative therapy assets. We

expect to continue confidential discussions with franchise leaders

interested in our molecular imaging and regenerative therapeutic

pipelines. We expect discussions to advance materially toward

partnerships over the course of this year.

Conference Call Access Information

The company will host a conference call to discuss results on, May 15, 2008, at 9:00 a.m. Eastern Daylight Time. To access the conference call, please dial 877-795-3649 for domestic and 719-325-4817 international. The code for this conference call is 1073493. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of our website,, within 48 hours following the conference call and will be available through Thursday, May 29th, 2008.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Alseres is a trademark and Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.


Sharon Correia - 508-497-2360 ext. 224

Alseres Pharmaceuticals, Inc.

Adam Friedman - 212-981-2529 ext. 18

Adam Friedman Associates

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
2. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. Raises $5 Million
5. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
6. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
7. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
8. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
9. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
10. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
11. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
Post Your Comments:
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... company, has announced the final product specifications for TRACTUS, the world’s first sterile ... in the United States in response to the FDA’s recent Unique Device Identifier ...
(Date:10/9/2015)... ... October 09, 2015 , ... Cambias Insurance Agency, ... communities, is initiating a combined charity effort with Animal Rescue New Orleans in ... Louisiana. , Animal Rescue New Orleans is a non-profit organization committed to ...
(Date:10/9/2015)... ... , ... ViewPoint Center, a teen mental health hospital for youth ... stigma associated with mental illness causes many to hide away in shame rather than ... teens with mental illness , providing teens with comprehensive diagnostic assessment and treatment. ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... placement counseling, recently opened its newest office in Maryland – its Bethesda ... with a background as a project management technology consultant to many of the ...
(Date:10/9/2015)... Florida (PRWEB) , ... October 09, 2015 , ... A variety of race options will ... Treatment of Co-occurring Disorders on Sunday, October 18, at Al Lopez Park, 4810 North Himes ... and will include the choice of a 5K run or walk and a one-mile walk, ...
Breaking Medicine News(10 mins):
... to be used for treating patients with osteoporosis//, but scientists ... observe the changes in the bone mineral density. ,A ... drug strontium ranelate have an effect on the bone mineral ... advantage of the treatment procedure. The recent studies on the ...
... out that people who regularly drink large amount of alcohol are ... causes than binge drinkers, who drink a lot of alcohol in ... had more than enough attention given to young alcohol consumers who ... maximum, these people may be more at risk from violent assaults ...
... An interesting prospective study undertaken by the researchers at Massachusetts ... shown that higher intake of low-fat dairy may lower the ... II diabetes, either the body does not produce enough insulin ... the body to be able to use sugar. Type II ...
... have shown that placebo treatment can reduce the nature ... experiences. ,Placebo treatment consists of dummy medication or ... tablets, saline water injections etc. ,In the new ... have shown that placebo treatment can effectively control the ...
... said that stomach infections caused by Helicobacter pylori ... ,Helicobacter pylori are common bacteria that reside ... causes stomach infections. Previous research had connected the ... tracts, and ischemic heart disease. ,Researchers have ...
... the proper structure// and function of cell membranes and ... animal studies have shown that high intake of polyunsaturated ... is a clouding of the normally clear lens of ... of blindness in the world today. Besides the physical ...
Cached Medicine News:
(Date:10/8/2015)... Oct. 8, 2015  Allergan plc (NYSE: AGN ... it will hold its R&D Day on November 4, ... – to 1:00 p.m. PT). The company will also ... at 9:00 a.m. ET (6:00 a.m. PT). ... --> Logo - ...
(Date:10/8/2015)... CAMBRIDGE, Mass. , Oct. 8, 2015 /PRNewswire/ ... has awarded approximately $40 million to the Broad ... whole genome sequencing of 20,000 individuals, as well ... sequencing and metabolite profiling. Trans-Omics for ... an initial step toward a larger initiative, which ...
(Date:10/8/2015)... FRANCISCO , Oct. 8, 2015  Nektar Therapeutics ... the Company,s pain and oncology portfolio during an Investor ... - 3:30 p.m. Eastern Time in New ... carcinoma.  Details of the NKTR-214 Phase 1/2 clinical program ... CD122-biased immune-stimulatory cytokine designed to preferentially stimulate the production ...
Breaking Medicine Technology:
... (SIX: RO, ROG; OTCQX: RHHBY) announced today that the David ... be using the Roche LightCycler ® 480 System, a ... gene expression and genetic variation, in advanced cancer research. ... 480 System to support several key areas of research it ...
... 2011 /PRNewswire/ -- Royal Philips Electronics ... States availability of the Ingenia MRI system, the ... Previously available in Europe, Canada and Japan, the ... Food and Drug Administration. Driven by Philips commitment ...
Cached Medicine Technology:
CDIs new improved Implant Stabilizer has super-soft elastic bands with lace trim....
Bras and Breast Support...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
Medicine Products: